
NEWSLETTER ON GLOBAL CLINICAL TRIALS

Volume 2, October 2022 (first half)

**Industry Insights for:
Biotech, Pharma, MedTech, Medical Device**



Our biweekly clinical trial newsletter can help you quickly identify new important trials and important conditions.

For more detailed information or more specific business intelligence analysis, please contact us at contact@buttontech.us

Table of Contents

1	SIGNIFICANT CLINICAL TRIALS BY DURATION	1
2	SIGNIFICANT CLINICAL TRIALS BY ENROLLMENT	2
3	CONTACT US FOR CUSTOMIZED BUSINESS INTELLIGENCE ANALYSIS	4

The big data platform built by BUTTON covers business intelligence, clinical data, regulatory information and supply chain data in Biotech/MedTech/Medical Device industry.

In this newsletter, we want to give you a glimpse of some features and insights about BUTTON's database on global clinical trials, which can be accessible in a more comprehensive manner on our platform. Herein, you can browse and get a quick understanding on the issues mentioned above – just as an iceberg, the most important dimensions are below the surface. If you get interested and want to grasp more details, information and data, please contact us at contact@buttontech.us.

1 Significant Clinical Trials by Duration


Generally speaking, a clinical trial with a longer duration may bring more business opportunities to other companies, such as CROs.

Table 1 shows **the expected durations of clinical trials** (all in Phase 3) initiated between October 1st and 15th 2022, ranked in descending order. Figure 1 shows **the average expected durations by indications** for these clinical trials, ranked in descending order.

**Table 1: Significant Clinical Trials by Expected Durations
(Initiated between 10/01/2022-10/15/2022)**

Indication	Phase	Indication	Start Date	Duration(years)
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	Neoadjuvant Chemotherapy	2022-10-15	9.5
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	HER2-negative Breast Cancer	2022-10-15	9.5
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	Hormone Receptor-positive Breast Cancer	2022-10-15	9.5
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	Pathological Complete Response	2022-10-15	9.5
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	Objective Response Rate	2022-10-15	9.5
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormi	Phase 3	Fasting Mimicking Diet	2022-10-15	9.5
A Study of Imlunestrant Versus Standard Endocrine Therapy in Partic	Phase 3	Breast Neoplasms	2022-10-04	9.5
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)	Phase 3	Acute Myeloid Leukemia	2022-10-01	9.4
A Study of QL1706 Combined With Platinum-containing Chemotherap	Phase 3	Carcinoma, Non-Small-Cell Lung	2022-10-01	9
Adjuvant Melatonin for Uveal Melanoma	Phase 3	Uveal Melanoma	2022-10-02	8.3
Adjuvant Melatonin for Uveal Melanoma	Phase 3	Uveal Melanoma, Posterior, Medium/Large S	2022-10-02	8.3
Adjuvant Melatonin for Uveal Melanoma	Phase 3	Eye Cancer, Intraocular Melanoma	2022-10-02	8.3
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA	Phase 3	Head and Neck Cancer	2022-10-06	8.2
NiraParib Maintenance After Carboplatin and Paclitaxel in optimalLy c	Phase 3	Clear Cell Carcinoma	2022-10-01	8
Platform Study of Circulating Tumor DNA Directed Adjuvant Chemoth	Phase 3	Colon Cancer	2022-10-01	8

**Figure 1: Significant Indications by Average Expected Durations
(Initiated between 10/01/2022-10/15/2022)**



Our database shows that, for the clinical trials that were initiated in the first half of October 2022, the average duration is longest for clinical trials in Neoadjuvant Chemotherapy, HER2-negative Breast Cancer and Hormone Receptor-positive Breast Cancer, and they each will take roughly 9.5 years.

If you would like to know more comprehensive lists of indications, clinical trials and sponsors, please contact us at contact@buttontech.us.

2 Significant Clinical Trials by Enrollment


Generally speaking, a clinical trial with more enrollments may bring more business opportunities to other companies, such as CROs.

Table 2 shows **the enrollments of clinical trials** (mostly in Phase 3) initiated between October 1st and 15th 2022, ranked in descending order. Figure 2 shows **the total enrollments by indications** for these clinical trials, ranked in descending order.

**Table 2: Significant Clinical Trials by Enrollments
(Initiated between 10/01/2022-10/15/2022)**

Title	Phase	Indication	Enrollment
Vellore Typhoid Vaccine Impact Trial	Phase 4	Typhoid Fever	72,000
A Study of Tirzepatide (LY3298176) on the Reduction on Mo	Phase 3	Obesity	15,000
A Study of Tirzepatide (LY3298176) on the Reduction on Mo	Phase 3	Overweight	15,000
A Study of Imlunestrant Versus Standard Endocrine Therapy	Phase 3	Breast Neoplasms	6,000
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Hea	Phase 3	COVID-19	4,000
Primary Thromboprophylaxis in Patients With Malignancy an	Phase 3	Cancer	1,828
Primary Thromboprophylaxis in Patients With Malignancy an	Phase 3	Venous Thromboembolism	1,828
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Brain Diseases	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Mental Disorders	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Alzheimer Disease	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Central Nervous System Disease	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Dementia	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Nervous System Diseases	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Tauopathies	1,500
A Study of Donanemab (LY3002813) in Participants With Ea	Phase 3	Neurodegenerative Diseases	1,500

**Figure 2: Significant Indications by Total Enrollments
(Initiated between 10/01/2022-10/15/2022)**





If we check out the correlation between clinical trial's enrollment number and indication, it can be seen that infectious diseases are an important part in this month's newly-initiated clinical trials, such as Typhoid Fever and COVID-19; On the other hand, weight-related scenario also receives lots of attention, with the second most enrollment from obesity and overweight, respectively.

3 Contact Us for Customized Business Intelligence Analysis

Please contact us at contact@buttontech.us if you are interested in getting to know about latest clinical trials in more details, such as:

- **Active PIs;**
- **Active sponsors;**
- **Latest clinical trials for particular enrollment sizes, durations, indications, and eligibility criteria;**
- **Leading clinical experts in a particular field/area;**
- **Other customized business intelligence analysis for clinical trials.**

Powered by BUTTON Platform

2672 Bayshore Parkway, Suite 1001, Mountain View, CA 94043

WEB: <https://www.button-corp.com> EMAIL: contact@buttontech.us